Skip to main content
. 2019 Oct 9;14(10):e0223639. doi: 10.1371/journal.pone.0223639

Fig 3. Light and dark pathway coverage for HNSCC mutation and copy number enriched pathways.

Fig 3

Diagram of the subsets of Reactome pathways in HNSCC that are mutation-enriched or copy-number alteration enriched, with drug-targeted subsets labeled for each. Percentages shown in the figure are out of the total number pathways used for this analysis (1650). Of the HNSCC-specific mutation enriched pathways, 34% are targetable by FDA approved cancer drugs (light pathways) and 66% are open for drug development (dark pathways). Of the HNSCC-specific enriched pathways, 38% are targetable by FDA-approved cancer drugs (light pathways) and 62% are open for drug development (dark pathways.